Samson Clinical has concluded participant enrolment for its SAM-002 Phase III clinical trial assessing sublingual minoxidil in male pattern hair loss, also known androgenetic alopecia (AGA). The ...
The MarketWatch News Department was not involved in the creation of this content. MELBOURNE, Australia, Aug. 6, 2025 /PRNewswire/ -- Samson Clinical (Samson), a pharmaceutical company focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results